Dante Genomics receives grant for a whole genome sequencing project to measure utility of pharmacogenomics in a real, clinical setting
Dante Genomics, a global leader in genomics and precision medicine, is pleased to announce that the Company’s co-founder and CEO Andrea Riposati presented as an opening speaker on Tuesday, September 27, 2022 at the 77th United Nations General Assembly (UNGA) Science Summit, where he unveiled the Company’s Digital Health Population Genomics Program in Europe, including living labs, which are groundbreaking pilot studies with fast impact on a country’s society and digital health.
Dante Genomics, a global leader in genomics and precision medicine, is pleased to announce that the Company’s co-founder and CEO Andrea Riposati presented as an opening speaker on Tuesday, September 27, 2022 at the 77th United Nations General Assembly (UNGA) Science Summit, where he unveiled the Company’s Digital Health Population Genomics Program in Europe, including living labs, which are groundbreaking pilot studies with fast impact on a country’s society and digital health.
Dante Labs, a global leader in genomics and precision medicine, is pleased to announce the company has been selected as the genetic testing provider for Abu Dhabi Stem Cells Center (ADSCC).
Dante Labs, a global leader in genomic information and precision medicine, announces new genomic driven biosimulation and significant progress made to its drug discovery program, demonstrating the value of the Dante Platform.
Dante Labs, a global leader in genomics and precision medicine, announces the establishment of the first of its Medical Genomics Boards, strengthening the Company’s mission and research activity in this new frontier of healthcare, using genomics to promote prevention and treatment.
Dante Labs, a global leader in genomics and precision medicine, today announced the launch of Dante Genomics, an online marketplace portal specifically dedicated to healthcare providers, clinics, researchers and governments which will offer advanced genomic services for research and clinical applications.
Dante Labs, a global leader in genomics and precision medicine, today announced it has partnered with The Renato Dulbecco Foundation to deliver more personalized therapies in rare diseases, oncology and COVID-19. Protelica, the groundbreaking US biotechnology company, has licensed its library of billions of pronectines nanoantibodies and a portfolio of 12 patents to The Renato Dulbecco Foundation.
In a study published in The Journal of Prevention of Alzheimer’s Disease (JPAD) – and co-authored by the Department of Psychiatry and the Behavioral Sciences, and Department of Neurology, Keck
